Nectar Social | $10,600,000 | (Jun 6, 2025)
Baobab | $13,702,071 | (Jun 6, 2025)
Signify Bio | $15,000,000 | (Jun 6, 2025)
Certified by Founder
Lodge
Evommune
start up
United States
- Palo Alto, California
- 27/04/2023
- Series B
- $50,000,000
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.
Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.
Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
- Industry Biotechnology Research
- Website https://www.evommune.com/
- LinkedIn https://www.linkedin.com/company/evommune/
Voltrac | $2,286,772 | (Jun 6, 2025)
Rosebud | $6,000,000 | (Jun 6, 2025)
Allay Therapeutics | $57,500,000 | (Jun 6, 2025)
Impart Security | $12,000,000 | (Jun 6, 2025)
Flank | $10,000,000 | (Jun 6, 2025)
Obvio | $22,000,000 | (Jun 5, 2025)
Filament Syfter | $4,800,000 | (Jun 5, 2025)
Vivrelle | $62,000,000 | (Jun 5, 2025)
Sema4.ai | $25,000,000 | (Jun 5, 2025)